Whalesbook
USFDA ne di green signal!
Arey bhai, USFDA ne Alembic Pharmaceuticals ki generic Methotrexate injection ko finally approve kar diya hai. Ye approval company ke liye bahut strategic hai kyunki isse unki oncology aur autoimmune diseases ke liye banaye gaye products ki range aur strong ho jayegi. Ab ye injection 50 mg/2 ml multi-dose vials aur 1g/40 ml single-dose vials mein milegi. Ye Hospira, Inc. dwara pehle market kiye gaye original drug ke therapeutically equivalent hai.
Ye drug hai kiske liye?
Methotrexate injection ka use kai tarah ke cancers mein hota hai, jaise acute lymphoblastic leukemia, meningeal leukemia, osteosarcoma, aur breast cancer. Sirf cancer hi nahi, chronic inflammatory aur autoimmune disorders jaise rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, aur severe psoriasis mein bhi ye effective hai.
Pipeline aur Stock Update
Is approval ke saath, Alembic ki US generics pipeline mein ab 235 ANDAs ho gaye hain, jinmein se 217 ko final approval mil chuki hai. Aise regulatory approvals ke baad, typically Alembic ke stock price mein 1-5% tak ka movement dekha gaya hai. April 15, 2026 tak stock ₹734.80 par trade kar raha tha, jo 2.42% ka rise tha previous close se. Company ki market cap lagbhag ₹14,232.9 crore hai aur P/E ratio 22.68 ke aas-paas hai.
Market ka Scene Kya Hai?
Alembic ab globally USD 0.547 billion (2026 tak) vale Methotrexate market mein enter kar rahi hai, jiska 2.8% CAGR se badhne ka estimate hai. North America, especially US, is market ka bada share rakhta hai. Overall generic oncology drugs market USD 44.83 billion (2032 tak) tak ja sakta hai (6.2% CAGR), aur autoimmune therapeutics market USD 168.6 billion (2025) se USD 226.2 billion (2035) tak (3.0% CAGR) pahunchne ki ummeed hai.
Competition Aur Future
Lekin bhai, ye market kaafi competitive hai. Pfizer (Hospira) aur Teva Pharmaceuticals jaise bade players pehle se hain. Generics mein prices ko lekar bhi pressure rehta hai. Pichle 9 mahino mein stock mein 28% tak ki giraavat bhi dekhi gayi thi. Haalanki, analysts ne generally 'Buy' rating di hai aur target price ₹1000-₹1020 rakha hai, par kuch ne caution bhi dikhaya hai. Analysts ko ummeed hai ki Alembic ki revenue agli 3 saal mein 10.1% aur earnings 20.8% per annum badh sakti hai.